v3.25.4

Collaboration Agreements (Details) $ in Millions	1 Months Ended	12 Months Ended
	Nov. 30, 2022 item	Dec. 31, 2025 USD ($)
LigaChem Biosciences
Collaboration Agreements
Additional receivable on collaboration agreements, finalization of cost sharing		$ 0.4
Research Collaboration and Co-Development Agreement
Collaboration Agreements
Maximum number of antibody drug conjugates to be developed | item	3
Collaboration agreements cost sharing percentage (as a percent)	50.00%	50.00%
Collaboration arrangement reduction in expenses		$ 2.5

X

- Definition

Amount of additional receivable on finalization of costs sharing terms under collaborative agreements.

+ References

No definition available.

+ Details

Name:	nxtc_CollaborationAgreementsAdditionalReceivableOnFinalizationOfCostSharingTerms
Namespace Prefix:	nxtc_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Represents the collaboration agreements cost sharing percentage.

+ References

No definition available.

+ Details

Name:	nxtc_CollaborationAgreementsCostSharingPercentage
Namespace Prefix:	nxtc_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The amount of collaborative arrangement reduction in expense.

+ References

No definition available.

+ Details

Name:	nxtc_CollaborativeArrangementReductionInExpenseAmount
Namespace Prefix:	nxtc_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Represents the maximum number of antibody drug conjugates to be developed.

+ References

No definition available.

+ Details

Name:	nxtc_MaximumNumberOfAntibodyDrugConjugatesToBeDeveloped
Namespace Prefix:	nxtc_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=nxtc_LegochemBiosciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=nxtc_ResearchAndDevelopmentCollaborativeAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: